Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function
Life Science Alliance · 2026
DOI: 10.26508/lsa.202503335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2026. Verfasst von Fangkun Luan und 8 weiteren Autor:innen. Beteiligte Einrichtung: The School of Medicine, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-6, Glycolysis, CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
T cells are one of the most powerful weapons to fight cancer; however, T-cell exhaustion and dysfunction restrict their long-lasting function in antitumor immunity. B-cell lymphoma 6 (BCL6) has many functions in CD8 T cells; however, it is unclear how it regulates the effector function and exhaustion of CD8 cells. Overall, a low level of BCL6 mRNA in human cancer samples is associated with better outcomes, but high expression of BCL6 is specifically observed in cytotoxic CD8 T cells. We found that BCL6 deficiency in activated CD8 T cells enhanced tumor repression in multiple mouse models. More IL-2–expressing CD8 T cells and reduced proportions of exhausted or dysfunctional CD8 T cells were detected within tumors when Bcl6 was knocked out upon T-cell activation. Glycolysis was promoted, and GLUT3 expression was derepressed in BCL6-deficient CD8 T cells. The BCL6 inhibitor Fx1 promoted antitumor immunity in a T cell–dependent manner. These findings suggest a novel pathway to restore effector function of CD8 T cells by changing their energy use pathways to facilitate long-term tumor resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The School of Medicine, Nankai University, Tianjin, China.
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
- Department of Immunology, Suzhou Medical College of Soochow University, Suzhou, China.
- Molecular and Cell Biology Laboratory, The Salk Institute, La Jolla, CA, USA.
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA nemazee@scripps.edu yunli@scripps.edu cxiao@scripps.edu.
ORCID-Profile: Yunqiao Li, David Nemazee
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Luan, F., Li, Y., Ning, J., Tran, J. T., Blane, T. R., Bhargava, R., Huang, Z., Xiao, C., & Nemazee, D. (2026). Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function. Life Science Alliance. https://doi.org/10.26508/lsa.202503335
Vancouver
Luan F, Li Y, Ning J, Tran JT, Blane TR, Bhargava R, et al. Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function. Life Science Alliance. 2026. doi:10.26508/lsa.202503335
BibTeX
@article{Luan2026,
author = {Luan, Fangkun and Li, Yunqiao and Ning, Jia and Tran, Jenny Tuyet and Blane, Tanya R and Bhargava, Raag and Huang, Zhe and Xiao, Changchun and Nemazee, David},
title = {Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function},
journal = {Life Science Alliance},
year = {2026},
doi = {10.26508/lsa.202503335}
}
EUVIMED